RPL17 and non-small cell lung carcinoma: Overall survival (OS) for patients with metastatic disease significantly increased after the regulatory approval of PD-1 or PD-L1 inhibitors for NSCLC; currently, the majority of NSCLC patients receive PD-1/PD-L1 inhibitors as part of standard care, typically given as front-line therapy [41, 42].